Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 14, 2009 - Issue 2
Submit an article Journal homepage
187
Views
10
CrossRef citations to date
0
Altmetric
Reviews

Emerging drugs in the treatment of pancreatic cancer

Devalingam Mahalingam Clinical Investigator, University of Texas Health Science Center, Institute of Drug Development, Division of Cancer Research and Therapy Center, San Antonio, Texas 78229, USA +1 210 450 5970; +1 210 450 9823; [email protected]
,
Kevin R Kelly Clinical Investigator, University of Texas Health Science Center, Institute of Drug Development, Division of Cancer Research and Therapy Center, San Antonio, Texas 78229, USA +1 210 450 5970; +1 210 450 9823; [email protected]
,
Ronan T Swords Clinical Investigator, University of Texas Health Science Center, Institute of Drug Development, Division of Cancer Research and Therapy Center, San Antonio, Texas 78229, USA +1 210 450 5970; +1 210 450 9823; [email protected]
,
Jennifer Carew Clinical Investigator, University of Texas Health Science Center, Institute of Drug Development, Division of Cancer Research and Therapy Center, San Antonio, Texas 78229, USA +1 210 450 5970; +1 210 450 9823; [email protected]
,
Steffan T Nawrocki Clinical Investigator, University of Texas Health Science Center, Institute of Drug Development, Division of Cancer Research and Therapy Center, San Antonio, Texas 78229, USA +1 210 450 5970; +1 210 450 9823; [email protected]
&
Francis J Giles Clinical Investigator, University of Texas Health Science Center, Institute of Drug Development, Division of Cancer Research and Therapy Center, San Antonio, Texas 78229, USA +1 210 450 5970; +1 210 450 9823; [email protected]
Pages 311-328 | Published online: 26 May 2009

Bibliography

  • Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;58(2):71-96
  • Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363(9414):1049-57
  • Burris HA III, Moore MJ, Adersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15(6):2403-13
  • Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25(15):1960-6
  • Milella M, Bria E, Cuppone F, et al. Current status of targeted agents (TA) in advanced pancreatic cancer (APC): meta-analysis of randomized clinical trials (RCT). ASCO Meeting Abstracts 2008;26(15 Suppl):4637
  • Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969
  • Mahalingam D, Giles F. Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opin Ther Targets 2008;12(11):1389-401
  • Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221(1):59-66
  • Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230(6):776-82, discussion 782-774
  • Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350(12):1200-10
  • Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297(3):267-77
  • Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299(9):1019-26
  • Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26(21):3496-502
  • Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127(11):1335-9
  • White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001;8(10):758-65
  • Klaassen DJ, Macintyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil–an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3(3):373-8
  • Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19(9):1592-9
  • Loehrer PJ, Powell MECH, Wagner L, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 [abstract 4506]. J Clin Oncol 2008;26(20 Suppl)
  • Rocha-lima CM. New directions in the management of advanced pancreatic cancer: a review. Anti Cancer Drugs 2008;19(5):435-46
  • Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23(15):3509-16
  • Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine plus oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 2006;24(18):180s
  • Sultana A, Smith CT, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007;25(18):2607-15
  • Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000;156:1821
  • Hahn SA, Kern SE. Molecular genetics of exocrine pancreatic neoplasms. Surg Clin North Am 1995;75(5):857-69
  • Hansel DE, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 2003;4(1):237-56
  • Howe JR, Conlon KC. The molecular genetics of pancreatic cancer 54. Surg Oncol 1997;6(1):1-18
  • Lemoine NR. Molecular advances in pancreatic cancer. Digestion 1997;58(6):550-6
  • Sakorafas GH, Tsiotos GG. Molecular biology of pancreatic cancer: potential clinical implications. BioDrugs 2001;15(7):439-52
  • Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol 1996;23(2):251-75
  • Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 2006;47(1):15-31
  • Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26(22):3291-310
  • Shields JM, Pruitt K, McFall A,et al. Understanding Ras: ‘it ain't over ‘til it's over'. Trends Cell Biol 2000;10(4):147-54
  • Bancroft CC, Chen Z, Dong G, et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 2001;7(2):435-42
  • Grunewald K, Lyons J, Frohlich A, et al. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 1989;43(6):1037-41
  • Smit VT, Boot AJ, Smits AM, et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16:7773
  • Calhoun ES, Jones JB, Ashfaq R, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 2003;163(4):1255-60
  • Gangarosa LM, Sizemore N, Graves-Deal R. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J Biol Chem 1997;272(30):18926-31
  • Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265(14):7709-12
  • Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22(20):7004-14
  • Han H, Bearss DJ, Browne LW, et al. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002;62(10):2890-6
  • Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control 2000;7(5):421-7
  • Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev 2005;6(8):635-45
  • Baudino TA, Mckay C, Pendeville-samain H, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002;16(19):2530-43
  • Ram PT, Iyengar R. G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation. Oncogene 2001;20(13):1601-6
  • Trevino JG, Summy JM, Gray MJ, et al. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res 2005;65(16):7214-22
  • Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005;24(36):5552-60
  • Caldas C, Hahn SA, Da COSTA, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8(1):27-32
  • Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57(15):3126-30
  • Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005;331(3):851-8
  • Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 1994;54(6):1556-60
  • Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29(2):117-29
  • Bierie B, Moses HL. Tumour microenvironment: TGF-beta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6(7):506-20
  • Truty MJ, Urrutia R. Basics of TGF-beta and Pancreatic Cancer. Pancreatology 2007;7(5-6):423-35
  • Freeman JW, Dearmond D, Lake M, et al. Alterations of cell signaling pathways in pancreatic cancer. Front Biosci 2004;9:1889-98
  • Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000;19(21):2607-11
  • Sato N, Ueki T, Fukushima N, et al. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2002;123(1):365-72
  • Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev 2006;5(9):769-84
  • Saldanha G. The Hedgehog signalling pathway and cancer. J Pathol 2001;193(4):427-32
  • Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391(6662):90-2
  • Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8(10):743-54
  • Thayer SP, di Magliano MP, HeiserPW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425(6960):851-6
  • Martin ST, Sato N, Dhara S, et al. Aberrant methylation of the Human Hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. Cancer Biol Therapy 2005;4(7):728-33
  • Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003;425(6960):846-51
  • Morton JP, Mongeau ME, Klimstra DS, et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci USA 2007;104(12):5103-8
  • Miyamoto Y, Hosotani R, Wada M, et al. Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers. Oncology 1999;56(1):73-82
  • Friess H, Lu Z, Graber HU, et al. Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 1998;43(3):414-21
  • Friess H, Lu Z, Andren-sandberg A, et al. Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg 1998;228(6):780-7
  • Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87(2):161-7
  • Van Cutsem E, Van De Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22(8):1430-8
  • Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001;19(15):3447-55
  • Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
  • Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol 2006;24(4):656-62
  • Maurel J, Martin-richard M, Conill C, et al. Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2006;66(5):1391-8
  • Philip PAJB, Fenoglio-preiser C, Zalupski M, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25 No. 18S (20 Suppl):LBA4509
  • Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2(1):e17
  • Lievre A, Bachet JB, Le Corre, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66(8):3992-5
  • Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23(25):5900-9
  • Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6(1):1-12
  • Knowlden JM, Jones HE, Barrow D, et al. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib (‘Iressa’) response and resistance. Breast Cancer Res Treat 2008;111(1):79-91
  • Rodon J, Desantos V, Ferry RJ Jr, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008;7(9):2575-88
  • Beltran PJPM, Moody G, Chung Y, et al. Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models [abstract 4617]. J Clin Oncol 2008;26(20 Suppl)
  • Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13(19):5834-40
  • Moser C, Schachtschneider P, Lang SA, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer 2008;44(11):1577-86
  • Piao W, Wang Y, Adachi Y, et al. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol Cancer Ther 2008;7(6):1483-93
  • Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007;14(3):285-94
  • Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Diff 2008;15(4):678-85
  • Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
  • Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88(10):2239-45
  • Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997;3(8):1309-16
  • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
  • Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
  • Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
  • Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB80303). In: ASCO Annual Meeting Proceedings. Edition. 2007:199s
  • Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24(35):5601-8
  • Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocrine Relat Cancer 2001;8(3):219-25
  • Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12(1):144-51
  • Wallace JA, Locker G, Nattam S, Kasza K, et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a phase II trial of the University of Chicago Phase II Consortium. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25 No. 18S (20 Suppl):4608
  • Michaelson MDAS, Ryan DP, Mcdermott DF, et al. A phase I dose-finding study of sunitinib (SU) in combination with gemcitabine (G) in patients (pts) with advanced solid tumors [abstract 14522]. Clin Oncol 2008;26(20 Suppl)
  • Abe T, Toyota M, Suzuki H, et al. Upregulation of BNIP3 by 5-aza-2′-deoxycytidine sensitizes pancreatic cancer cells to hypoxia-mediated cell death. J Gastroenterology 2005;40(5):504-10
  • Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22(22):4456-62
  • Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26(13):2139-46
  • Haklai R, Elad-sfadia G, Egozi Y, Kloog Y. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 2008;61(1):89-96
  • End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61(1):131-7
  • Lobell RB, Omer CA, Abrams MT, et al. Evaluation of farnesyl: protein transferase and geranylgeranyl: protein transferase inhibitor combinations in preclinical models. Cancer Res 2001;61(24):8758-68
  • Venkatasubbarao K, Choudary A, Freeman JW. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res 2005;65(7):2861-71
  • Caponigro F. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. Anti Cancer Drugs 2002;13(8):891-7
  • Van Cutsem E, van de Velde H, Karasek, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22(8):1430-8
  • Ryan DP, Eder JP Jr, Puchlaski T, et al. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res 2004;10(7):2222-30
  • Herbert Hurwitz RA, Prager D, Hecht J, et al. Phase I Pharmacokinetic Trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers [abstract 717]. Proc Am Soc Clin Oncol 2000;19
  • Kato K, Cox AD, Hisaka MM, et al. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992;89(14):6403-7
  • Cox CD, Hisaka MM, BussJE, Der CJ. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol Cell Biol 1992;12(6):2606-15
  • Seufferlein T, Van Lint J, Liptay S, et al. Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. Gastroenterology 1999;116(6):1441-52
  • Raymond P, Perez JWSI, Steven R, et al. Phase II Trial of ISIS 2503, an antisense inhibitor of H-ras, in patients (Pts) with advanced pancreatic carcinoma (CA) [abstract 628]. Proc Am Soc Clin Oncol 2001;20
  • Alberts SR, Schroeder M, Erlichman C, et al. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol 2004;22(24):4944-50
  • Vaha-koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007;254(2):178-216
  • Yap TA, Brunetto A, Pandha H, et al. Reovirus therapy in cancer: has the orphan virus found a home? Expert Opin Invest Drugs 2008;17(12):1925-35
  • Strong JE, Coffey MC, Tang D, et al. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17(12):3351-62
  • Vidal L, Pandha H, Spicer J, Harrington KJ, et al. A phase I study of reolysin given intravenously to patients with advanced malignancies. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24 No. 18S (20 Suppl):3064
  • Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296(5573):1655-7
  • Mamane Y, Petroulakis E, Rong L, et al. eIF4E--from translation to transformation. Oncogene 2004;23(18):3172-9
  • Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005;123(4):569-80
  • Wolpin AFHBM, Ryan DP, Abrams TA, et al. Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer [abstract 4614]. J Clin Oncol 2008;26(20 Suppl)
  • Shroff HQXRT, Varadhachary GR, Kaseb A, et al. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: the results of two prospective phase II studies. 2009 Gastrointestinal Cancers Symposium Abstract No: 246
  • Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8(3):179-83
  • Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 2004;431(7005):200-5
  • Leblanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10(1):66-75
  • Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12(6):611-20
  • Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000;102(1):1-4
  • Korsmeyer SJ, Wei MC, Saito M, et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000;7(12):1166-73
  • Mahalingam D, Szegezdi E, Keane M, et al. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 2008
  • Oldenhuis C CM, Sleijfer S, Gietema JA, et al. A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin [abstract 3540]. J Clin Oncol 2008;26(20 Suppl)
  • Kindler HLLEG, Stephenson J, Wiezorek J, et al. Safety and efficacy of AMG 655 in combination with gemcitabine in patients with metastatic pancreatic cancer. 2009 Gastrointestinal Cancers Symposium Abstract No: 246
  • Sanchez P, Hernandez AM, Stecca B, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci USA 2004;101(34):12561-6
  • Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004;431(7009):707-12
  • Feldmann G, Fendrich V, Mcgovern K, et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008;7(9):2725-35
  • LoRusso CMRPM, Borad MJ, Vernillet L, et al. A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors [abstract 3516]. J Clin Oncol 2008;26(20 Suppl)
  • Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev 2004;5(10):781-91
  • Bagatell R. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 2004;3(8):1021-30
  • Kim HL, Cassone M, Otvos L Jr, Vogiatzi P. HIF-1alpha and STAT3 client proteins interacting with the cancer chaperone Hsp90: therapeutic considerations. Cancer Biol Ther 2008;7(1):10-4
  • Song D, Chaerkady R, Tan AC, et al. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther 2008;7(10):3275-84
  • Lang SA, Moser C, Gaumann A, et al. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 2007;13(21):6459-68
  • Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61(13):5137-44
  • Toyonaga T, Nakano K, Nagano M, et al. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett 2003;201(1):107-16
  • Sinibaldi D, Wharton W, Turkson J, et al. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 2000;19(48):5419-27
  • Garcia R, Bowman TL, Niu G, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20(20):2499-513
  • Turkson J, Bowman T, Garcia R, Caldenhoven E, et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998;18(5):2545-52
  • Chan KS, Carbajal S, Kiguchi K, et al. Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res 2004;64(7):2382-9
  • Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008;18(2):254-67
  • Trevino JG, Summy JM, Lesslie DP, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006;168(3):962-72
  • Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 2007;13(14):4233-44
  • Fletcher S, Turkson J, Gunning PT. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 2008;3(8):1159-68
  • Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19(56):6613-26
  • Uronis HEKB, Blobe G, Hsu SD, et al. A phase I study of gemcitabine + dasatinib (GD) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. 2009 Gastrointestinal Cancers Symposium. Abstract 276
  • Tabernero JAC, Hoekman K, Hurwitz HI, et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25No. 18S(20 Suppl):3520
  • Hong DSRK, Supko JG, Lawrence DP, et al. Phase I trial with a novel oral NF-κB/STAT3 inhibitor RTA 402 in patients with solid tumors and lymphoid malignancies [abstract 3517]. J Clin Oncol 2008;26(20 Suppl)
  • Kumagai T, Wakimoto N, Yin D, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007;121(3):656-65
  • Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001;20(24):3139-55
  • Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001;134(7):573-86
  • Kanda T, Tada M, Imazeki F, et al. 5-aza-2′-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. Oncol Rep 2005;14(4):975-9
  • Missiaglia E, Donadelli M, Palmieri M, et al. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene 2005;24(1):199-211
  • Fountzilas G, Bobos M, Kalogera-Fountzila A, et al. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest 2008;26(8):784-93
  • Beltran PJPM, Moody G, Chung Y, et al. Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2008;26 No. 15S(20 Suppl):4617
  • Sarantopoulos JACM, Mulay M, Romero O, et al. A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G) [abstract 3583]. J Clin Oncol 2008;26(20 Suppl)
  • Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23(31):8033-40
  • Wolpin BMAFH, Ryan DP, Abrams TA, et al. Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer [abstract 4614]. J Clin Oncol 2008;26(20 Suppl)
  • Shroff RTHQX, Varadhachary GR, Kaseb A, et al. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies. 2009 Gastrointestinal Cancers Symposium Abstract 246
  • Mita M, Sankhala K, Abdel-karim I, et al. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Invest Drugs 2008;17(12):1947-54
  • Powers MV, Workman P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 2007;581(19):3758-69
  • Uronis HEKB, Blobe G, Hsu SD, et al. A phase I study of gemcitabine + dasatinib (GD) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors. 2009 Gastrointestinal Cancers Symposium Abstract 246

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.